Press release: APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401

Important development step for promising cell therapy

Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors
Innovative new manufacturing and treatment process enables outpatient treatment within one day from cell collection to reinfusion
Phase Ib clinical trial evaluates immunological effects as well as safety and tolerability of APN401 in patients with advanced-stage solid tumors
APN401 is an autologous cell therapy designed to inhibit the immune checkpoint Cbl-b using RNAi technology